Market revenue in 2023 | USD 63,392.6 million |
Market revenue in 2030 | USD 126,657.3 million |
Growth rate | 10.4% (CAGR from 2023 to 2030) |
Largest segment | Contract manufacturing |
Fastest growing segment | Contract Manufacturing |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Contract Development, Contract Manufacturing |
Key market players worldwide | Catalent Inc, Lonza Group Ltd, Recipharm, Siegfried Holding AG, Thermo Fisher Scientific Inc, Labcorp Drug Development, Jabil Inc, Syngene, IQVIA Holdings Inc, Almac Group, Ajinomoto Co Inc, Alcami, Vetter Pharma-Fertigung |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to healthcare contract development and manufacturing organization market will help companies and investors design strategic landscapes.
Contract manufacturing was the largest segment with a revenue share of 77.99% in 2023. Horizon Databook has segmented the Asia Pacific healthcare contract development and manufacturing organization market based on contract development, contract manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific’s healthcare contract development & manufacturing organization market is expected to witness lucrative growth owing to the growth in opportunities, especially in Japan, China, and India. Factors such as improved regulatory framework, high scope for cost savings, increased complexity in product designs, and growing number of medical device companies in the region are expected to drive the Asia Pacific market.
Furthermore, availability of skilled workforce in the region at a lower cost than the U.S. is anticipated to propel the market. China holds the largest share in the Asia Pacific market, primarily due to high healthcare expenditure and rapid introduction of advanced medical devices. Increasing regulatory focus on quality control for manufacturing is one of the key factors expected to drive its market over the forecast period.
Asia Pacific has a number of regulatory agencies, such as Pharmaceuticals and Medical Devices Agency (PMDA) in Japan; the Ministry of Food and Drug Safety (MFDS) in South Korea; the Therapeutic Goods Administration (TGA) in Australia; and the Singapore Health Sciences Authority (HSA) in Singapore. Their strong influence over the market is expected to provide lucrative growth opportunities in the region.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific healthcare contract development and manufacturing organization market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific healthcare contract development and manufacturing organization market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account